Articles

March 15, 2023

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON–(BUSINESS WIRE)–Mar. 15, 2023– Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company…

View details
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON–(BUSINESS WIRE)–Mar. 15, 2023– Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company…

View details
4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights

March 15, 2023 Download PDF EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, ‘4DMT’), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, today announced full year 2022 financial results and provided operational highlights. “We are proud to have validated 4DMT’s Therapeutic Vector…

View details